Benchmark analyst Robert Wasserman downgrades Danaher (NYSE:DHR) from Buy to Hold.
Competitor Recall Continues To Show Opportunities For ResMed
ResMed Inc (NYSE:RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus…